A combined omics study on activated macrophages—enhanced role of STATs in apoptosis, immunity and lipid metabolism

Ashok Reddy Dinasarapu¹,†, Shakti Gupta¹,†, Mano Ram Maurya², Eoin Fahy¹, Jun Min¹, Manish Sud², Merrill J. Gersten¹, Christopher K. Glass³ and Shankar Subramaniam¹,2,3,4,*

¹Department of Bioengineering, ²San Diego Super Computer Center, ³Department of Cellular and Molecular Medicine and ⁴Department of Chemistry and Biochemistry, University of California San Diego, CA 92093, USA

Associate Editor: Martin Bishop

ABSTRACT

Background: Macrophage activation by lipopolysaccharide and adenosine triphosphate (ATP) has been studied extensively because this model system mimics the physiological context of bacterial infection and subsequent inflammatory responses. Previous studies on macrophages elucidated the biological roles of caspase-1 in post-translational activation of interleukin-1β and interleukin-18 in inflammation and apoptosis. However, the results from these studies focused only on a small number of factors. To better understand the host response, we have performed a high-throughput study of Kdo2-lipid A (KLA)-primed macrophages stimulated with ATP.

Results: The study suggests that treating mouse bone marrow-derived macrophages with KLA and ATP produces ‘synergistic’ effects that are not seen with treatment of KLA or ATP alone. The synergistic regulation of genes related to immunity, apoptosis and lipid metabolism is observed in a time-dependent manner. The synergistic effects are produced by nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and/or activator protein (AP)-1 through regulation of their target cytokines. The synergistically regulated cytokines then activate signal transducer and activator of transcription (STAT) factors that result in enhanced immunity, apoptosis and lipid metabolism; STAT1 enhances immunity by promoting anti-microbial factors; and STAT3 contributes to downregulation of cell cycle and upregulation of apoptosis. STAT1 and STAT3 also regulate glycerolipid and eicosanoid metabolism, respectively. Further, western blot analysis for STAT1 and STAT3 showed that the changes in transcriptomic levels were consistent with their proteomic levels. In summary, this study shows the synergistic interaction between the toll-like receptor and purinergic receptor signaling during macrophage activation on bacterial infection.

Availability: Time-course data of transcriptomics and lipidomics can be queried or downloaded from http://www.lipidmaps.org.

Contact: shankar@ucsd.edu

Supplementary information: Supplementary data are available at Bioinformatics online.

Received on March 20, 2013; revised on July 22, 2013; accepted on August 8, 2013

*To whom correspondence should be addressed.
†The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.

1 INTRODUCTION

Lipopolysaccharide (LPS) is an endotoxin from bacterial cell wall that stimulates leukocytes via a toll-like receptor (TLR)-4 pathway (Peck et al., 2004). Kdo2-lipid A (KLA) is an active component of LPS with an analogous response (Raetz et al., 2006) in activating macrophages. The TLR-4 signaling pathway ultimately mediates the release of pro- and anti-inflammatory factors by activating mitogen-activated protein kinase cascade, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and/or activator protein (AP)-1 (Maurya et al., 2013; Raetz et al., 2006; Rutledge et al., 2012). In this study, we have primed macrophages with KLA before stimulation with ATP. KLA priming represents bacterial exposure, which elicits subsequent release of ATP in the extracellular space from inflamed, damaged or dying cells. ATP then acts via autocrine and paracrine signaling and is interpreted as a ‘danger signal’ by immune cells. These events induce the transcription of pro-inflammatory mediators through the transcription factors (TFs) NF-kB and AP1 (Junger, 2011). Interestingly, a model system of ATP stimulation of LPS-primed macrophages exhibited increased cell death compared with the macrophages treated with either ATP or LPS alone (Mehta et al., 2001; Pfeiffer et al., 2007). The increased apoptosis, caused by LPS and ATP treatment, was reduced with caspase-1 inhibitors but not with mitogen-activated protein kinase, protein kinase (PK)-C, or PK-A inhibitors (Mehta et al., 2001; Pfeiffer et al., 2007). In addition to LPS and ATP treatment, there have been a number of studies on LPS-primed macrophages stimulated by various ligands including air particles, lysophosphatidic acid, interferon (IFN)-γ, IL-4 and toxicants (El Chartouni and Rehli, 2010; Glaser et al., 1993; Griffiths et al., 1995; Gupta et al., 2010; Imrich et al., 1999; Le Feuvre et al., 2002; Pelegrin et al., 2008; Pestka and Zhou, 2006; Uehara et al., 2002). Moreover, sequential activation of one or more TLR receptors by their respective ligands was studied in LPS-primed macrophages (De Nardo et al., 2009; Ilievski and Hirsch, 2010). Most of these studies showed the importance of selected genes or cytokines in LPS-primed macrophages to mimic the biological context of bacterial infection and subsequent immune response.

In addition to the cytokine response, LPS-stimulated macrophages showed changes in lipids such as eicosanoids, sphingolipids, sterols, glycerolipids and glycerophospholipids (Chang et al., 2001; Dennis et al., 2010; Desanctis et al., 1994; Drapier and Petit, 1986; Hauton and Evans, 2002; Knapp and English,
2 METHODS

2.1 Transcriptomic and lipidomic data

Transcriptomic and lipidomic data were generated in mouse bone marrow-derived macrophages (BMDM) over 7 time points, 0.25, 0.5, 1, 2, 4, 8 and 20h, with three different stimulus conditions: 2 mM ATP (A), 100 ng/ml KLA (K) and KLA/ATP (KA) treatments by the Lipid Metabolites and Pathways Strategy (LIPID MAPS) consortium (Dennis et al., 2010; Subramaniam et al., 2011). To confirm the activation of macrophages, TNF-α was used as a marker (Guerra et al., 2003; Tonetti et al., 1995). For the KA group, treatment with K was performed 4h before treatment with A; this was done to mimic the biological phenomenon of KLA activation preceding ATP release as a ‘danger signal’ from immune cells (Supplementary Fig. S1). For the transcriptomic data, two biological replicates were measured with dye swap using Agilent custom microarrays. The arrays contained 45 214 spots with 38 838 unique probes and 21 676 unique mouse genes. The data were normalized using the locally weighted scatterplot smoothing (Lowess) method (Yang et al., 2002). For lipidomic data, three biological replicate experiments were carried out using liquid chromatography and mass spectrometry techniques. The detailed protocols are described in LIPID MAPS Web site (http://www.lipidmaps.org/protocols/index.html).

2.2 Statistical analysis

2.2.1 Regulated list of probes and genes

To identify significantly regulated probes, variance modeling-based t-test (implemented as Cyber-T) was used (Baldi and Long, 2001). Cyber-T uses a Bayesian estimate of the variance among the probe intensities. We applied Cyber-T in two different ways. In the Case I analysis, a paired t-test was used to find the differentially regulated probes between treatment and its control group (Fig. 1). In the Case II analysis, an unpaired t-test was used to identify the probes that are differentially regulated between single and combined treatment groups; specifically, KA data were used as the treatment group and K or A data as control group. For this analysis, the raw intensity values of K, A and KA data were used under the assumption that the (true) control intensity values are approximately same across the three conditions (see Section 2.2.2). We chose to use raw intensity values in the Case II analysis, instead of fold changes with respect to controls, because variance of the data, used to calculate the t-scores, should be estimated locally among probes with similar raw intensity values. In both analyses, a gene was identified as significantly regulated if its associated P-value was ≤0.001. To analyze the differentially regulated probes,
we mapped them to their Entrez gene IDs and obtained the unique list of genes. Probes mapping to the same gene, but with opposite regulated expression, were removed from further analysis.

Generally, multiple testing correction methods (Dudoit and Laan, 2008) such as false discovery rate (FDR) and Bonferroni correction are used for refining P-values. However, we did not use either correction methods for the following reasons: Bonferroni correction was deemed too stringent, and FDR created a problem in identifying the list of regulated genes for early time points in A data. For example, FDR did not produce any significantly regulated gene for 15 or 30 min in the ATP treatment because of low number of differentially regulated genes at those time points.

2.2.2 Outlier detection One of the key assumptions in using an unpaired r-test for the treatment effect gene expression values in the Case II analysis is the stability of the (true) control expression values across the different ligand groups (K, A and KA). However, in some cases a probe’s control value for one of the ligands was significantly different from the other two, causing the r-test results to be misleading. To address this issue, the Grubbs test for outliers (Grubbs, 1950) was used on the (true) control expression values to identify potential outliers. Probes were removed from statistical analysis if one of their control values was more extreme than either twice or half the mean of all three control values. The second test was necessary to ensure that the results from the Grubbs test did not overestimate the number of potential outliers because of the small sample size (N = 3). The condition for the Grubbs test is given below:

$$\text{max}_{i = 1, \ldots, N} \left| \frac{Y_i - \bar{Y}}{s} \right| > \frac{N - 1}{\sqrt{N}} \sqrt{\frac{t_{(N-2),N-2}^2}{N - 2 + t_{(N-2),N-2}^2}}$$

The hypothesis of no outliers was rejected if the above condition is satisfied where $\bar{Y}$ is the sample mean, $s$ is the standard deviation, $N$ is the sample size and $t_{(N-2),N-2}$ is the critical value of r-distribution. We used a P-value threshold of 0.05. For further information, see Supplementary Table S1.

2.2.3 Functional enrichment analyses Enrichment analysis was performed to identify the significance of the changes in the differentially regulated genes based on different biological processes. Gene Ontology (Ashburner et al., 2000) and Kyoto encyclopedia of genomes and genomes pathways (Kanehisa and Goto, 2000) were used to identify overrepresented annotation groups by comparing a ‘selected’ list with a ‘background’. A comprehensive gene list of the microarray was considered as a background. The hypergeometric distribution was used to find the exact probabilities to compute enrichment likelihoods (Hsiao et al., 2005):

$$P(\geq s) = \sum_{i=s}^{b} {\binom{N-b}{k-i} \binom{b}{i}} / \binom{N}{k}$$

where $b$ is the number of ‘background’ genes annotated with the term/pathway, $s$ is the number of ‘selected’ genes annotated with the term/pathway, $N$ is the total number of ‘background’ genes and $k$ is the total number of ‘selected’ genes.

2.2.4 TF-target gene mapping TRANSFAC® Release 2010.4 data were used as the source for TF—target gene information. For each time point, the TFs in the differentially regulated list of genes were selected and mapped to their subset of target genes that were also differentially regulated at the same or a later time point. As there are 7 time points, there exist 21 iterations [n (n − 1)/2, where n = 7 time points]. The regulated network was created and visualized using GraphViz (www.graphviz.org) and/or Cytoscape (www.cytoscape.org). Upregulated genes are colored red (or solid nodes) and downregulated genes are colored green (or dashed nodes); the time points 1, 2, 3, 4, 5, 6 and 7 represent 0.25, 0.5, 1, 2, 4, 8 and 20 h, respectively (Fig. 2).

2.2.5 Correlation/clustering of lipid profiles Pearson correlation is used to find the similarity between two time courses (Anderson, 1984; Egghe and Leydesdorff, 2009). For our data, we used a weighted correlation, in which the time points were weighted in proportion to the preceding time interval, because the measurements were taken at non-uniform time intervals (Dennis et al., 2010). For example, the earlier time points had less weight because the measurements were taken more frequently in the beginning than at the end (Subramaniam et al., 2011). Assuming a weight vector of $W = [w_1, w_2, w_3, w_4, w_5, w_6, w_7]$, the weighted mean, the weighted standard deviation, the weighted z-score and the correlation were computed as follows (where $n = 7$, the number of time points):

$$\text{Mean} \ : \ \bar{X}_w = \frac{\sum_{i=1}^{n} w_i X_i}{\sum_{i=1}^{n} w_i} \quad \text{Standard deviation} \ : \ s_{w} = \sqrt{\frac{\left(\sum_{i=1}^{n} w_i (Y_i - \bar{X}_w)^2\right) - \frac{\left(\sum_{i=1}^{n} w_i Y_i\right)^2}{\left(\sum_{i=1}^{n} w_i\right)^2}}{\sum_{i=1}^{n} w_i}}$$

$$\text{z-score} \ : \ z_{w, n} = \left(\frac{n}{n - 2}\right)^{1/2} \frac{X - \bar{X}_w}{s_w} \quad \text{Correlation} \ : \ r_n = \frac{\sum_{i=1}^{n} w_i (X_{w,i} - \bar{X}_{w}) (Y_{w,i} - \bar{Y}_{w})}{\sqrt{\sum_{i=1}^{n} w_i (X_{w,i} - \bar{X}_{w})^2 \sum_{i=1}^{n} w_i (Y_{w,i} - \bar{Y}_{w})^2}}$$

The above equations were extended for two data matrices X and Y, with the rows representing different genes or lipids and the columns representing different time points. Correlation-based hierarchical clustering (Langfelder et al., 2008) was used to lay out the variables (lipid concentrations or gene fold changes) in the data heat map. The data shown are the differences in treatment versus control values scaled by the maximum absolute value of each row. The statistics/bioinformatics toolbox of Matlab® (Mathworks, 1994) was used to perform hierarchical clustering with the customized correlation defined earlier in the test [parameters: linkage-method = average; cut-off criterion = distance (=1 - r); cut-off = 0.40]. Different colors for the names of the lipids indicate the clusters (Fig. 3).

3 RESULTS

We used paired t-test between experiments and control (Case I analysis) and unpaired t-test between the three treatments (Case II analysis) to identify differentially regulated genes (see Section 2). The results from the paired t-test in the Case I analysis showed few significantly regulated genes in the A group at 15 min (0.25 h), with the number increasing from 15 min to 4 h and then decreasing (Fig. 1a and b). In the case of K and KA groups, 4 h priming with K before the first measurement affected many genes, so that the number of significantly regulated genes at 15 min was ~3000. In the K group, the number of significantly regulated genes peaked at 30 min (equivalent to 4 h 30 min after treatment with K) and decreased substantially after 30 min. In contrast, the KA group showed the number of regulated genes to remain high for most of the time points.

To identify the similarities and the differences across the different treatments, Venn diagrams were drawn for all the time points (Fig. 1b and Supplementary Table S2). The results suggested that there is a significant number of regulated genes
unique to the KA treatment (zone c in the Venn diagram), not regulated in either the K or the A treatment alone. However, Case I analysis has two problems. The first problem relates to false 'KA-unique' genes that showed up as differentially regulated genes in the KA treatment because of slight differences in P-values near the threshold. For example, a gene with a P-value just below the threshold in the KA treatment, but just above it in the K or A treatment, would, erroneously, be identified as unique to the KA treatment. The second problem relates to missed 'KA-unique' genes, genes differentially regulated in all three treatment groups, but significantly more regulated in the KA group than in the K or the A group as a result of synergistic effect. To circumvent these problems, the Case II analysis of the unpaired t-test between the treatment groups was adopted.

In the Case II analysis, two independent unpaired t-tests were performed: between KA and K groups, and between KA and A groups. The results from the first t-test produced the list of the genes that are differently regulated in the KA group compared with the K group. These genes were either affected by A or synergistically affected by KA (Fig. 1c, circle ‘A’). Similarly, the genes from the second t-test were either affected by K or synergistically affected by KA (Fig. 1c, circle ‘K’). The intersection between the two t-test results, then, produced the list of genes that are differently regulated in the KA group compared with both the K and the A groups (Fig. 1c, intersection ‘aik’). Uniquely regulated genes in the KA group were categorized into synergistic and antagonistic subsets based on the direction and the magnitude of the regulation in the two comparisons. ‘Synergistic regulation’ is used here in a less restricted manner to include genes significantly regulated by KA as compared with K and A alone. This view includes but goes beyond the traditional definition of synergism (Chou, 2010); this approach was taken to identify all the genes regulated by both K and A. A gene was considered to be synergistically regulated if its regulation in the KA group versus both the K and the A group was significantly higher or lower. For example, a gene that shows a 10-fold change in the KA group but only 5-fold changes in both the K and the A group was considered to be synergistically upregulated. Other possible cases of the synergistic effect are defined in Supplementary Figure S2. On the other hand, a gene was considered to be antagonistic if its regulation in the KA group was upregulated with respect to the K group but downregulated with respect to the A group, or vice versa.

Pathway enrichment for the Case II synergistic genes was done for all the time points to find the pathways that are synergistically affected by the KA treatment. Figure 1d shows the histogram of the number of regulated genes for all the time points in selected top enriched pathways. TFs from the Case II synergistic set of genes were also mapped to the subset of their target genes, which showed synergistic regulation at the same or future time points (Fig. 2). For Case I, TF-target genes mapping, see Supplementary Figure S3. The results of Case II analyses are presented here.

3.1 Signaling pathways

Pro- and anti-inflammatory cytokines: K and/or A signaling cascades include NF-κB and AP1 effector molecules in the activation of pro- and anti-inflammatory cytokines (Akira and Takeda, 2004; Tonetti et al., 1995). In our data, K influenced API via Jun, whereas A activated API via both Jun and Fos. We found evidence of synergistic regulation of NF-κB and API in the KA treatment. NF-κB was synergistically upregulated

Fig. 2. Transcriptional regulatory network of Case II analysis spanning 7 time points (aik region in Fig. 1c). The TF to target interaction data was obtained from TRANSFAC. Edges between TFs and their targets were assigned when both were synergistically regulated, with the target regulated at the same or a later time point. The numbers 1, 2, 3, 4, 5, 6 and 7 represent 0.25, 0.5, 1, 2, 4, 8 and 20 h, respectively. The red color (or solid nodes) indicates upregulation and the green color (or dashed nodes) indicates downregulation. Genes discussed in this manuscript are represented as rectangles. Dashed edge is added manually (see details in Section 4)
starting from 1 h. ATF 1/2/3 and Junb showed statistically significant synergistic regulation at 20 h, although evidence of synergistic regulation was seen from 4 h onward. The synergistic activation of NF-κB and AP1 supported the synergistic effect in TLR-4 signaling (Fig. 1d, Supplementary Fig. S4). The activated TLR-4 signaling promoted expression of pro- and anti-inflammatory cytokines, evidenced by enrichment of the cytokine-cytokine receptor interaction pathway from 30 min onward (Supplementary Table S3). Interleukins (ILs) are targets of TLR-4 signaling, and many of them showed, as expected, synergistic regulation in the KA treatment. For example, pro- and anti-inflammatory IL-6, IL-10 and IL-12β were initially upregulated by CEBPβ, NF-κB and AP1 from 1 h onward (Fig. 2). TRANSFAC data mapping (Fig. 2) also shows that IL-27 was synergistically upregulated by NF-κB and Irf1, IL-12β by JunB and Fos and IL-18 by Fos.

JAK-STAT signaling pathway: Cytokines such as IL-6, IL-10, and IFN-β1 activate JAK-STAT signaling pathway via autocrine signaling (Murray, 2007). The pathway enrichment showed that JAK-STAT signaling was upregulated from 1 h onward (Supplementary Table S3). This is due to Jak2 and STATs, with the exception of STAT6, showing synergistic upregulation at 20 h. In particular, STAT3 was synergistically upregulated as early as 1 h, although statistical significance was not observed until 8 h. From Figure 2, TRANSFAC mapping shows that STAT3 synergistically upregulated Ly6a, which is known to promote phagocytosis by macrophages (Long et al., 2011). Other members of the Ly6 complex were also synergistically upregulated in the KA treatment. Besides STAT3’s involvement in phagocytosis, STAT1 has been shown to upregulate anti-microbial/viral factors such as Ly6a, Nos2, Hamp, Psmb9, TAP1 and Tgtp (Cramer and Klemsz, 1997; Lafuse et al., 1995; Pagani et al., 2011). Thus, STATs, particularly STAT1 and STAT3, that were synergistically upregulated in the KA treatment, are the key players in promoting phagocytic and anti-microbial functions of macrophages at later time points.

Cell cycle and apoptosis: Mapping of KA synergistic genes in the cell cycle pathway indicated that CycH and Myc were synergistically downregulated in KA (Supplementary Fig. S6). Myc has been shown to promote cell cycle progression by directly inducing CycD and sequestration of Kip1 (Amati et al., 1998; Bouchard et al., 1999). The synergistic upregulation of Bnip1 (an inhibitor of Myc) and Kip1 (an inhibitor of CycA) is consistent with the downregulation of Myc in the KA treatment. Known upstream inhibitors of cyclins (CycA/B/D/E), such as GSK3, Ink4d, Kip1/2, Cip1, GADD45b (a target of STAT3) and 14-3-3σ, were also synergistically upregulated. Thus, synergistic upregulation of cell cycle inhibitors and synergistic downregulation of cyclins accounted for the synergistic downregulation of the cell cycle. Pathway enrichment analysis also showed synergistic upregulation of apoptosis and p53 signaling pathways 1 h onward (Fig. 1d). The number of synergistically regulated genes in these pathways was initially low, but increased at 20 h indicating elevated cell death at later hours. This analysis observed synergistic upregulation of apoptotic genes such as caspase 1, 3, 4, 7, 8 and 12, as well as IL-1, FAS and Apaf1 (Le Feuvre et al., 2002; Supplementary Fig. S5), and synergistic downregulation of anti-apoptotic genes (Bcl2) at 20 h. These results are also consistent with the observed reduction in DNA levels in KA experiments relative to control, K or A experiments (Supplementary Fig. S11).
3.2 Lipid metabolism

**Eicosanoids:** Eicosanoids, specifically prostaglandins (PGs), showed increased production in the KA treatment (Fig. 3a, Supplementary Fig. S7). The increase in PGs was in agreement with the observed synergistic upregulation of Ptgs2. TRANSFAC mapping (Fig. 2) shows that the synergistic upregulation of Ptgs2 was due to CEBPβ at early hours and Irf1, Irf2, Usf1 and AP1 at later hours. Further, Ptges and Alox12 also showed synergistic regulation at 20h, consistent with the increased production of PGE2 and 12-HETE, respectively.

**Sphingolipids:** Increased concentrations of ceramide (Cer) and dihydroceramide were observed in the KA treatment (Fig. 3b and Supplementary Fig. S10). The enhanced synthesis (or accumulation) of Cer can be attributed to the synergistic upregulation of sphingolipid de novo synthesis enzyme, Sptlc2, in the KA treatment. Although sphingomyelin hydrolysis can also contribute to Cer levels via the upregulation of sphingomyelin synthase 2, reversible nature of this enzymatic reaction makes its contribution to the production of Cer less clear.

**Sterols:** The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase was upregulated with respect to control in the KA treatment (Case I analysis), in agreement with the increased lanosterol and desmosterol in the KA treatment (Fig. 4). However, the concentrations of these sterols such as lanosterol and desmosterol were lower in the KA treatment than in the K treatment for most time points, suggesting ATP is influencing de novo synthesis of cholesterol and its precursors in KA treatment. These concentration profiles can be explained by the synergistic downregulation of several enzymes in the KA treatment involved in lanosterol and desmosterol synthesis: lanosterol synthase (Lss), lanosterol 14α-demethylase (CYP51A1) and hydroxysteroid (17-beta) dehydrogenase 7 (HSD17B7). Furthermore, as seen in Figure 2 and Supplementary Figures S8 and S9, sterol regulatory element-binding protein1 (SREBP1) and SREBP2, known to regulate fatty acid and sterol biosynthesis enzymes including Lss, CYP51A1 and HSD17B7 (Rawson, 2003; Shimano, 2001), are synergetically downregulated. Thus, synergistic downregulation of many genes in the sterol biosynthetic pathway contributes to reduced concentration profiles of sterols in the KA treatment compared with the profiles in the K treatment.

**Glycerolipids:** The profile of triglycerides (TGs), well-known glycerolipids, in Figure 4 shows an increased level in the KA treatment with respect to K and A treatments for most of the time points. These lipidomic data are explained by the synergistic upregulation of aldehyde dehydrogenase 1 family, member B1 (Aldh1b1), 1-acylglycerol-3-phosphate O-acyltransferase 4 (Apgat4), phosphatidic acid phosphatase type 2B (Ppap2b) and diacylglycerol O-acyltransferase 1 and 2 (Dgat1 & Dgat2), which are involved in the production of TGs from glycerols. Accumulation of TGs can also result from the reduced hydrolysis of TGs. In particular, lipoprotein lipase (LPL) is the rate-limiting enzyme for the hydrolysis (lipolysis) of TGs, and its expression has been shown to be suppressed by STAT1 and activated by SREBP2 at the transcriptional level (Hogan and Stephens, 2003; Wang and Eckel, 2009). Synergistic upregulation of STAT1 and downregulation of SREBP2 can lead to the synergistic downregulation of LPL in the KA treatment (Fig. 2), with an expected reduction in TG hydrolysis contributing to synergistic TGs accumulation (Fig. 4).

4 DISCUSSION

The activation of macrophages using KLA (or LPS) and/or ATP has been the subject of long-standing investigations because of their roles in inflammation, immunity and apoptosis. KLA treatment represents exposure of immune cells to bacteria; subsequently ATP is released from macrophages as a ‘danger signal’. To globally study the macrophage role in inflammation and immunity, LIPID MAPS performed transcriptomic and lipidomic experiments on BMDM treated with KLA and/or ATP. Although this analysis is based on transcriptomic data, there is evidence of good correlation between gene and protein levels (Sabido et al., 2012). We have validated the changes at the transcriptional level for STAT1, STAT3 and SREBP2 with their proteomic levels using western blotting (see Supplementary Fig. S13). KLA (or LPS) treatment is known to release ATP into extracellular space. This concentration is generally much smaller than the concentration needed to sufficiently stimulate the macrophages in vitro and may produce a small amount of ATP-mediated autocrine signaling. In this analysis, such effects were ignored. Further, we identified differentially regulated genes and performed functional enrichment analysis for pathways and Gene Ontologies, and used TRANSFAC for TF to target gene mapping.

A time-dependent synergistic regulation of genes in both same and different signaling pathways and biological processes in the KA treatment was observed. In particular, both K and A influenced NF-κB and AP1 to produce synergistic regulations at the signaling level. At the transcriptional level, this synergistic effect was observed as early as 1 h. The synergistic activation of NF-κB and AP1 can also come from autocrine signaling through IL-1α or IL-1β. As a result, target chemokines and cytokines of NF-κB and AP1, such as IL-1, IL-6, IL-10 and Cxcl10, showed synergistic regulation for most of the time points. As IL-10 is known to inhibit the synthesis of several cytokines, including IFNγ, IL-2

![Fig. 4. Profiles of sterols and TGs. BMDM were treated with KLA and/or ATP. The error bars shown for the experimental data represent the standard error of mean](http://bioinformatics.oxfordjournals.org/)

2740
TGs because of reduced lipolysis. STAT1 downregulated LPL and promoted accumulation of arachidonic acid production in eicosanoid metabolism. Usf1 and AP1 at later hours. Similarly, IL-10 was regulated by macrophages (Feingold, 1995). In addition, time-dependent regulation of TFs and their target genes was also observed. For example, Ptgs2 was regulated by CEBPβ at early hours and Irf1, Irf2, Usp1 and API at later hours. Similarly, IL-10 was regulated by CEBPβ at early hours and JunB at later hours. STAT1, SREBP1 and SREBP2 and their targets showed synergistic regulation at 20 h.

The changes at the transcriptional level are also reflected in the changes in the level of corresponding lipids (Supplementary Table S5). The synergistic activation and release of IL-1β, IL-18 and caspase1 in macrophages treated with LPS and/or ATP were observed in several previous studies (He et al., 2013; Kavita and Mizel, 1995). In addition, time-dependent regulation of TFs and their target genes was also observed. For example, Ptgs2 was regulated by CEBPβ at early hours and Irf1, Irf2, Usp1 and API at later hours. Similarly, IL-10 was regulated by CEBPβ at early hours and JunB at later hours. STAT1, SREBP1 and SREBP2 and their targets showed synergistic regulation at 20 h.

In summary, our analysis suggests that the synergistic activation of macrophages in the KA treatment occurred through the activation NF-kB and API, which, in turn, activated cytokine release. The cytokine effector functions synergistically activated STATs, particularly STAT1 and STAT3, that lead to enhanced immunity, apoptosis and lipid metabolism. STAT1 played a prominent role in enhanced immunity by regulating anti-microbial factors. STAT3 was important in regulating cell cycle and enhancing apoptosis. In addition, STAT1 and STAT3 regulated TGs and eicosanoids metabolism, respectively. The observed synergistic regulations were time-dependent, encompassing multiple genes that span key pathways related to immunity, apoptosis and lipid metabolism and highlight the complexity of the combined TLR and purinergic receptor activation of macrophage activation during bacterial infection.

Funding: NIH grant U54 GM69338-04 (LIPID MAPS) and NIDDK Grant P01-DK074868.

Conflict of Interest: none declared.

REFERENCES


